Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: exploratory analysis of the proportional hazards assumption. - Yajima S; Yoshida S; Masuda H; Fujii Y (Translational andrology and urology, 2026)